Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials

Atherosclerosis

Volumn 223, Issue 2, 2012, Pages 251-261

  Morrone, Doralisa ^a   Weintraub, William S ^a   Toth, Peter P ^b,c   Hanson, Mary E ^d   Lowe, Robert S ^d   Lin, Jianxin ^d   Shah, Arvind K ^d   Tershakovec, Andrew M ^d  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b CGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ezetimibe; Hypercholesterolemia; Statin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84864753387     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.016     Document Type: Review

References (65)

1. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
2. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
3. World Health Organization Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk 2007, World Health Organization, Geneva, Switzerland.
4. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
5. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009, 25:567-579.
6. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
7. Steinberg B.A., Bhatt D.L., Mehta S., et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J 2008, 156:719-727.
8. Waters D.D., Brotons C., Chiang C.W., et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009, 120:28-34.
9. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyorala K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940.
10. Alexander K.P., Blazing M.A., Rosenson R.S., et al. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther 2009, 14:49-58.
11. * Trial). Am J Cardiol 2003, 92:152-160.
12. Dembowski E., Davidson M.H. A review of lipid management in primary and secondary prevention. J Cardiopulm Rehabil Prev 2009, 29:2-12.
13. Sudhop T., Reber M., Tribble D., et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009, 50:2117-2123.
14. Jia L., Betters J.L., Yu L. Niemann-Pick C1-Like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol 2011, 73:239-259.
15. Tang W., Jia L., Ma Y., et al. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver. Biochim Biophys Acta 2011, 1811:549-555.
16. Toth P.P., Catapano A., Tomassini J.E., Tershakovec A.M. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clin Lipidol 2010, 5:655-684.
17. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40:2125-2134.
18. Kerzner B., Corbelli J., Sharp S., et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003, 91:418-424.
19. Melani L., Mills R., Hassman D., et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003, 24:717-728.
20. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415.
21. Goldberg A.C., Sapre A., Liu J., Capece R., Mitchel Y.B. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004, 79:620-629.
22. Feldman T., Koren M., Insull W., et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004, 93:1481-1486.
23. Ballantyne C.M., Blazing M.A., King T.R., Brady W.E., Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004, 93:1487-1494.
24. Bays H.E., Ose L., Fraser N., et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004, 26:1758-1773.
25. Ballantyne C.M., Abate N., Yuan Z., King T.R., Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (vytorin) versus atorvastatin in patients with hypercholesterolemia: the vytorin versus atorvastatin (VYVA) study. Am Heart J 2005, 149:464-473.
26. Catapano A.L., Davidson M.H., Ballantyne C.M., et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006, 22:2041-2053.
27. Goldberg R.B., Guyton J.R., Mazzone T., et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006, 81:1579-1588.
28. Rodney R.A., Sugimoto D., Wagman B., et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc 2006, 98:772-778.
29. Robinson J.G., Ballantyne C.M., Grundy S.M., et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol 2009, 103:1694-1702.
30. Gagne C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1084-1091.
31. Dobs A.S., Guyton J.R., McClusky D., et al. Coadministration of ezetimibe with simvastatin. J Am Coll Cardiol 2003, 41:227A.
32. Stein E., Stender S., Mata P., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004, 148:447-455.
33. Gaudiani L.M., Lewin A., Meneghini L., et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005, 7:88-97.
34. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005, 80:587-595.
35. Brohet C., Banai S., Alings A.M., Massaad R., Davies M.J., Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005, 21:571-578.
36. Farnier M., Volpe M., Massaad R., Davies M.J., Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005, 102:327-332.
37. Cruz-Fernandez J.M., Bedarida G.V., Adgey J., Allen C., Johnson-Levonas A.O., Massaad R. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005, 59:619-627.
38. Barrios V., Amabile N., Paganelli F., et al. Lipid-altering efficacy of switching from atorvastatin 10mg/day to ezetimibe/simvastatin 10/20mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005, 59:1377-1386.
39. Constance C., Westphal S., Chung N., et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40mg compared with atorvastatin 20mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007, 9:575-584.
40. Conard S.E., Bays H.E., Leiter L.A., et al. Efficacy and safety of ezetimibe added on to atorvastatin (20mg) versus uptitration of atorvastatin (to 40mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol 2008, 102:1489-1494.
41. Leiter L.A., Bays H., Conard S., et al. Efficacy and safety of ezetimibe added on to atorvastatin (40mg) compared with uptitration of atorvastatin (to 80mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol 2008, 102:1495-1501.
42. Farnier M., Averna M., Missault L., et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009, 63:547-559.
43. Zieve F., Wenger N.K., Ben Yehuda O., et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40mg in Patients > or=65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol 2010, 105:656-663.
44. Robinson J.G., Davidson M., Shah A., et al. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. Aging Health 2007, 3:691-705.
45. Abramson B.L., Benlian P., Hanson M.E., Lin J., Shah A., Tershakovec A.M. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis 2011, 10:146.
46. Leiter L.A., Betteridge D.J., Farnier M., et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obes Metab 2011, 13:615-628.
47. Rossebo A.B., Pedersen T.R., Boman K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343-1356.
48. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
49. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431-1443.
50. Mikhailidis D.P., Lawson R.W., McCormick A.L., et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011, 6:1191-1210.
51. Bays H., Ezetimibe Expert Opin Investig Drugs 2002, 11:1587-1604.
52. Miettinen T.A., Strandberg T.E., Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000, 20:1340-1346.
53. van Himbergen T.M., Matthan N.R., Resteghini N.A., et al. Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 2009, 50:730-739.
54. Descamps O.S., De Sutter J., Guillaume M., Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?. Atherosclerosis 2011, 217:308-321.
55. Cohen J.C., Pertsemlidis A., Fahmi S., et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA 2006, 103:1810-1815.
56. Simon J.S., Karnoub M.C., Devlin D.J., et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics 2005, 86:648-656.
57. Sniderman A.D. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. J Clin Lipidol 2008, 2:36-42.
58. Sniderman A.D., Williams K., Contois J.H., et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcome 2011, 4:337-345.
59. Winkler K., Jacob S., Muller-Schewe T., Hoffmann M.M., Konrad T. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 2012, 220:189-193.
60. Ballantyne C.M., Raichlen J.S., Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (measuring effective reductions in cholesterol using rosuvastatin) trial. J Am Coll Cardiol 2008, 52:626-632.
61. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
62. Ballantyne C.M., Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005, 6:21-29.
63. Ridker P.M., MacFadyen J., Libby P., Glynn R.J. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Am J Cardiol 2010, 106:204-209.
64. Davidson M.H., Ballantyne C.M., Jacobson T.A., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011, 5:338-367.
65. Califf R.M., Lokhnygina Y., Cannon C.P., et al. An update on the IMProved reduction of outcomes: vytorin efficacy international trial (IMPROVE-IT) design. Am Heart J 2010, 159:705-709.